Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to aids treatment
PloS med
; 4(11): e305, Nov. 13, 2007. ilus, tab
Article
em En
| ColecionaSUS
| ID: biblio-945544
Biblioteca responsável:
BR1.1
ABSTRACT
Little is known about the long-term drug costs associated with treating AIDS in developing countries.Brazils AIDS treatment program has been cited widely as the developing worlds largest and mostsuccessful AIDS treatment program. The program guarantees free access to highly active antiretroviraltherapy (HAART) for all people living with HIV/AIDS in need of treatment. Brazil produces non-patentedgeneric antiretroviral drugs (ARVs), procures many patented ARVs with negotiated price reductions, andrecently issued a compulsory license to import one patented ARV. In this study, we investigate the driversof recent ARV cost trends in Brazil through analysis of drug-specific prices and expenditures between 2001and 2005.
Texto completo:
1
Coleções:
06-national
/
BR
Base de dados:
ColecionaSUS
Assunto principal:
Síndrome da Imunodeficiência Adquirida
/
Custos de Medicamentos
/
Terapia Antirretroviral de Alta Atividade
/
Antirretrovirais
/
Programas Nacionais de Saúde
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
País/Região como assunto:
America do sul
/
Brasil
Idioma:
En
Revista:
PloS med
Ano de publicação:
2007
Tipo de documento:
Article